Pharmablue / Papers / Implementation of a French Early Access Program for orphan drug patients in nominative & cohort program / BOOK_CLOSE_CASE_STUDY-1

BOOK_CLOSE_CASE_STUDY-1

BOOK_CLOSE_CASE_STUDY-1

14 March 2025

Pharmablue

Pharmablue

Did you like this article? Share on social networks:

email linkedin twitter link
Exploitant for Innovative Pharma Companies

Associated News

Benefits of using a third party Exploitant to run early access programs in France and more

Main benefits of outsourcing "Exploitant" status : Reminder : French regulatory authorities require having an...

Learn more
10 Years of commitment to treating rare diseases

Rare diseases: At the core of our mission At PharmaBlue, we’ve spent the past decade...

Learn more
How to take advantage of early access programs for your innovative treatments in France?

Known as Expanded Access Programs in the US, early access programs (EAP) allow access to...

Learn more